CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
{{output}}
Thirteen percent of non-small cell lung cancer (NSCLC) patients are estimated to have the KRAS G12C mutation. Sotorasib is a novel KRAS G12C inhibitor that has shown promising results in preclinical and clinical studies, granting its conditional approval by th... ...
